Next Article in Journal
Humoral Immunity against Measles in Mother–Infant Pairs during the First Year of Life in Greece: A Cross-Sectional Study
Next Article in Special Issue
A Novel Effective and Safe Vaccine for Prevention of Marek’s Disease Caused by Infection with a Very Virulent Plus (vv+) Marek’s Disease Virus
Previous Article in Journal
Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells
Previous Article in Special Issue
A Herpesvirus of Turkey-Based Vector Vaccine Reduces Transmission of Newcastle Disease Virus in Commercial Broiler Chickens with Maternally Derived Antibodies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 2
10.3390/vaccines9020142
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

by
Yulong Wang
1,2,
Nan Jiang
1,2,
Linjin Fan
1,2,
Li Gao
1,2,
Kai Li
1,
Yulong Gao
1,2,
Xinxin Niu
1,2,
Wenying Zhang
1,2,
Hongyu Cui
1,2,
Aijing Liu
1,2,
Qing Pan
1,
Changjun Liu
1,
Yanping Zhang
1,
Xiaomei Wang
1,2,3,* and
Xiaole Qi
1,2,*
1
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Avian Immunosuppressive Diseases Division, The Chinese Academy of Agricultural Sciences, Harbin 150069, China
2
OIE Reference Laboratory for Infectious Bursal Disease, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China
3
Jiangsu Co-innovation Centre for Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou 225009, China
*
Authors to whom correspondence should be addressed.
Vaccines 2021, 9(2), 142; https://doi.org/10.3390/vaccines9020142
Submission received: 23 December 2020 / Revised: 26 January 2021 / Accepted: 5 February 2021 / Published: 10 February 2021
(This article belongs to the Special Issue Vaccine Research against Significant Viral Diseases of Poultry)
Browse Figures
Versions Notes

Abstract

Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.
Keywords: novel variant infectious bursal disease virus; vaccine; viral-like particle novel variant infectious bursal disease virus; vaccine; viral-like particle

Share and Cite

MDPI and ACS Style

Wang, Y.; Jiang, N.; Fan, L.; Gao, L.; Li, K.; Gao, Y.; Niu, X.; Zhang, W.; Cui, H.; Liu, A.; et al. Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus. Vaccines 2021, 9, 142. https://doi.org/10.3390/vaccines9020142

AMA Style

Wang Y, Jiang N, Fan L, Gao L, Li K, Gao Y, Niu X, Zhang W, Cui H, Liu A, et al. Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus. Vaccines. 2021; 9(2):142. https://doi.org/10.3390/vaccines9020142

Chicago/Turabian Style

Wang, Yulong, Nan Jiang, Linjin Fan, Li Gao, Kai Li, Yulong Gao, Xinxin Niu, Wenying Zhang, Hongyu Cui, Aijing Liu, and et al. 2021. "Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus" Vaccines 9, no. 2: 142. https://doi.org/10.3390/vaccines9020142

APA Style

Wang, Y., Jiang, N., Fan, L., Gao, L., Li, K., Gao, Y., Niu, X., Zhang, W., Cui, H., Liu, A., Pan, Q., Liu, C., Zhang, Y., Wang, X., & Qi, X. (2021). Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus. Vaccines, 9(2), 142. https://doi.org/10.3390/vaccines9020142

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop